| RADIOPHARM-VENTURES-LLC |
RADIOPHARM-VENTURES-LLC |
90%
|
We have a pipeline of six licensed platform technologies and a joint venture with MD Anderson in Houston, one of the world’s leading cancer research centers, called “Radiopharm Ventures LLC” which ha… |
| LNTH |
Lantheus Holdings, Inc. |
72%
|
Reciprocal relationship from LNTH graph: tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutical diagnostics are unsuccessful. • The ext… |
| ASX |
ASE Technology Holding Co., Ltd. |
62%
|
Reciprocal relationship from ASX graph: Reciprocal relationship from RADX graph: Reciprocal relationship from ASX graph: Reciprocal relationship from RADX graph: Reciprocal relationship from ASX grap… |
| ASX-LIMITED |
ASX-LIMITED |
62%
|
s ( 154,728,303 ) ( 119,345,518 ) 35,876,956 20,660,151 Loss for the year ( 32,205,611 ) ( 42,570,656 ) Total comprehensive loss ( 32,205,611 ) ( 42,570,656 ) (b) Guarantees entered into by the paren… |
| DELAWARE-PHARMA15-CORPORATION |
DELAWARE-PHARMA15-CORPORATION |
62%
|
s of our drug candidates and related treatments will be available in the United States and worldwide from government health administration authorities, private health insurers and other organizations… |
| GRANT-THORNTON-AUDIT-PTY-LTD |
GRANT-THORNTON-AUDIT-PTY-LTD |
62%
|
. Basis for opinion We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the… |
| GRANT-THORNTON-AUSTRALIA-LIMITED |
GRANT-THORNTON-AUSTRALIA-LIMITED |
62%
|
. Basis for opinion We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the… |
| GRANT-THORNTON-INTERNATIONAL-LTD |
GRANT-THORNTON-INTERNATIONAL-LTD |
62%
|
. Basis for opinion We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the… |
| LANTHEUS-HOLDINGS-INC |
LANTHEUS-HOLDINGS-INC |
62%
|
ization of health technologies. As such, the financial information presented in the body of the financial report represents the results of the Group’s sole operating segment. The CODM continues to mo… |
| NANOMAB-TECHNOLOGY-LIMITED |
NANOMAB-TECHNOLOGY-LIMITED |
62%
|
eligibility to be recouped, to develop a pattern of expected percentage completion at each stage of the project. In doing so, management make judgments on the likelihood of overall project success, i… |
| NEVADA-RADIOPHARM-VENTURES-LLC |
NEVADA-RADIOPHARM-VENTURES-LLC |
62%
|
s of our drug candidates and related treatments will be available in the United States and worldwide from government health administration authorities, private health insurers and other organizations… |
| PHARMA15-CORPORATION |
PHARMA15-CORPORATION |
62%
|
eligibility to be recouped, to develop a pattern of expected percentage completion at each stage of the project. In doing so, management make judgments on the likelihood of overall project success, i… |
| PROSPECTS-OVERVIEW-RADIOPHARM-THERANOSTICS-LIMIT |
PROSPECTS-OVERVIEW-RADIOPHARM-THERANOSTICS-LIMIT |
62%
|
s of our drug candidates and related treatments will be available in the United States and worldwide from government health administration authorities, private health insurers and other organizations… |
| THERANOSTICS-LIMITED |
THERANOSTICS-LIMITED |
62%
|
iopharm Theranostics Limited Notes to the financial statements 30 June 2025 1 Segment information Management has determined, based on the reports reviewed by the chief operating decision maker that a… |
| TRIMT-GMBH |
TRIMT-GMBH |
62%
|
eligibility to be recouped, to develop a pattern of expected percentage completion at each stage of the project. In doing so, management make judgments on the likelihood of overall project success, i… |
| UNITED-STATES-FOREIGN-UNITED-STATES-PHARMA15-COR |
UNITED-STATES-FOREIGN-UNITED-STATES-PHARMA15-COR |
62%
|
tial ordinary shares. (n) Revenue recognition The group recognizes revenue as follows: Revenue from contracts with customers Revenue is recognized at an amount that reflects the consideration to whic… |
| UNITED-STATES-FOREIGN-UNITED-STATES-RADIOPHARM-V |
UNITED-STATES-FOREIGN-UNITED-STATES-RADIOPHARM-V |
62%
|
tial ordinary shares. (n) Revenue recognition The group recognizes revenue as follows: Revenue from contracts with customers Revenue is recognized at an amount that reflects the consideration to whic… |
